Oblimersen, Rituximab and Combination Chemotherapy in Treating Patients With Relapsed or Refractory Aggressive Non-Hodgkin's Lymphoma

Part of paid clinical trials in Chicago, Illinois.

Sponsor
National Cancer Institute (NCI)
Study ID
NCT00086944
Phase
PHASE1/PHASE2
Status
Completed

Conditions

  • Recurrent Adult Diffuse Large Cell Lymphoma
  • Recurrent Grade 3 Follicular Lymphoma
  • Recurrent Mantle Cell Lymphoma

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • oblimersen sodium — BIOLOGICAL
    Given IV
  • rituximab — BIOLOGICAL
    Given IV
  • ifosfamide — DRUG
    Given IV
  • carboplatin — DRUG
    Given IV
  • etoposide — DRUG
    Given IV
  • filgrastim — BIOLOGICAL
    Given SC
  • pegfilgrastim — BIOLOGICAL
    Given SC
  • laboratory biomarker analysis — OTHER
    Correlative studies

Study Details

This phase I/II trial is studying the side effects and best dose of oblimersen when given together with rituximab and combination chemotherapy and to see how well they work in treating patients with relapsed or refractory aggressive non-Hodgkin's lymphoma. Monoclonal antibodies such as rituximab can locate cancer cells and either kill them or deliver cancer-killing substances to them without harming normal cells. Drugs used in chemotherapy, such as ifosfamide, carboplatin, and etoposide, work in different ways to stop cancer cells from dividing so they stop growing or die. Oblimersen may increase the effectiveness of chemotherapy by making cancer cells more sensitive to the drugs

Key Dates

Start date
May 31, 2004
Status verified
Jan 2013
Primary completion
Jul 31, 2006

Study Design

Enrollment
25 participants (actual)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: Treatment (genase, combination chemotherapy)
    See detailed description.

Primary Outcome Measure

Toxicity graded using the NCI CTCAE version 3.0 [ Time Frame: Up to 3 years ]

Locations (1)

FacilityCityStateZIPSite coordinators
University of Chicago Comprehensive Cancer CenterChicagoIllinois60637-1470-

Find similar trials in Chicago, IL

By research site
University of Chicago Comprehensive Cancer Center· Chicago, IL

Related Studies